Kiora Pharmaceuticals (KPRX) Accounts Payables (2014 - 2026)
Kiora Pharmaceuticals' (KPRX) quarterly Accounts Payables came in at $594874.0 in Q1 2026, down 36.88% YoY from $942492.0 in Q1 2025, and down 43.9% on a QoQ basis from $1.1 million in Q4 2025.
Kiora Pharmaceuticals (KPRX) Accounts Payables (2014 - 2026) Analysis & Trends
Kiora Pharmaceuticals (KPRX) has 13 years of Accounts Payables data on file, last reported at $594874.0 in Q1 2026.
- Quarterly Accounts Payables fell 36.88% year-over-year to $594874.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $594874.0 (down 36.88% YoY) and the FY2025 annual result came in at $1.1 million, up 155.13% from the prior year.
- Accounts Payables fell to $594874.0 in Q1 2026, from $1.1 million in the prior quarter.
- In the past five years, Accounts Payables ranged from a high of $1.1 million in Q4 2025 to a low of $125412.0 in Q3 2023.
- A 5-year average of $510901.9 and a median of $415590.0 in 2024 frame the typical range for Accounts Payables.
- Annual changes were most pronounced in 2022 — Accounts Payables jumped 527.73% — and 2023, when it slumped 83.29%.
- Tracing KPRX's Accounts Payables over 5 years: stood at $1.0 million in 2022, then plunged by 79.54% to $206260.0 in 2023, then jumped by 101.49% to $415590.0 in 2024, then jumped by 155.13% to $1.1 million in 2025, then slumped by 43.9% to $594874.0 in 2026.
- The last three Accounts Payables figures came in at $594874.0 (Q1 2026), $1.1 million (Q4 2025), and $241471.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 35.57 Mn |
| 10 | Kiora Pharmaceuticals | 15.64 Mn | 15.64 Mn | - | 216,497.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 216,497.00 |
| Mar 31, 2026 | 594,874.00 |
| Dec 31, 2025 | 1.06 Mn |
| Sep 30, 2025 | 241,471.00 |
| Jun 30, 2025 | 282,537.00 |
| Mar 31, 2025 | 942,492.00 |
| Dec 31, 2024 | 415,590.00 |
| Sep 30, 2024 | 660,415.00 |
| Jun 30, 2024 | 268,638.00 |
| Mar 31, 2024 | 323,062.00 |
| Dec 31, 2023 | 206,260.00 |
| Sep 30, 2023 | 125,412.00 |
| Jun 30, 2023 | 131,319.00 |
| Mar 31, 2023 | 587,473.00 |
| Dec 31, 2022 | 1.01 Mn |
| Sep 30, 2022 | 749,192.00 |
| Jun 30, 2022 | 785,766.00 |
| Mar 31, 2022 | 302,263.00 |
| Dec 31, 2021 | 160,621.00 |
| Sep 30, 2021 | 424,889.00 |